Exchange: NASDAQ·Updated 07:41 AM EDT
DNLI logo

DNLIDenali Therapeutics Inc

$24.73
$0.00
(0.00%)
Pre-Market
Prev Close $24.73
EarningsAug 10
Mkt Cap$3.94B
Vol3,521.00
News
all
press releases
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Zacks
News Placeholder
More News
News Placeholder
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Zacks
News Placeholder
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos...
Yahoo! Finance: News
News Placeholder
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.
Zacks
News Placeholder
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Zacks
News Placeholder
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial
The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.
Stocktwits
News Placeholder
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
Key PointsADAR1 added 1,819,339 Denali Therapeutics shares; estimated trade value is $36.20 million (based on average prices from the first quarter of 2026...
Nasdaq News: Markets
News Placeholder
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Zacks
News Placeholder
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.read more...
Benzinga
News Placeholder
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
Key PointsAcquired 254,857 shares of Denali Therapeutics; estimated transaction value $5.07 million (based on quarterly average price...
Nasdaq News: Markets
<
1
2
...
>